Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, David A., Dang, Ha X., Zhao, Shuang G., Lloyd, Paul, Aggarwal, Rahul, Alumkal, Joshi J., Foye, Adam, Kothari, Vishal +55 more·2018·Cell
DOI 10.1016/j.cell.2018.06.039

Cited by (738)

Items 601–700 of 738

  1. Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer
    Jennifer Obasi, Komal Sharma, Navonil De Sarkar, Emmanuel S. Antonarakis, Deepak Kilari · 2024 · Clinical Genitourinary Cancer
  2. DNA Repair Capacity and Clinicopathological Characteristics in Puerto Rican Hispanic/Latino Patients with Metastatic Castration-Resistant Prostate Cancer
    Jaime L. Matta, Carmen Ortíz, Jarline Encarnación-Medina, Stephanie Torres-Caraballo, José Oliveras, Jong Y. Park, Monica Arroyo, Gilberto Ruiz-Deyá · 2025 · Cancers
  3. Epigenetic abnormalities and neuroendocrine differentiation in prostate cancer
    G. A. Kovchenko, Andrey V. Sivkov, Liudmila N. Lyubchenko, А. Д. Каприн · 2025 · Siberian Journal of Oncology
  4. Identifying prognostic targets in metastatic prostate cancer beyond AR
    Emily Feng, Eric Feng, Tracy J. Berg, Isabella S. Nguyen, Lilac G Nguyen, William S. Chen, Meng Zhang, D. Quigley, M. Sharifi, Hao-Long Li et al. · 2025 · FEBS Open Bio
  5. CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement
    Hao Li, Jindan Luo, Huaiyuan Liang, Bai Yanfeng, Jiandong Liu, Ting Wei, Liguo Wang, Hongshan Guo, Dan Xia, Haojie Huang et al. · 2025 · Cancer Research
  6. Genomic divergence between matched primary and metastatic tumors across cancer types: a pan-cancer analysis of 5,692 samples
    Yakup Ergün · 2025 · Expert Review of Anticancer Therapy
  7. Daidzein-engineered high-accumulation self-therapeutic nanoplatform drives androgen receptor degradation via ubiquitination-proteasome system to overcome enzalutamide resistance in castration-resistant prostate cancer
    Zhaoxiang Xie, Chunlei Dai, Zhi Xiong, Minghui Li, Liying Wang, Junjia Xie, Xinyin Li, Yi Zhao, Kaiwen Li, Jun Wu et al. · 2025 · Materials Today Bio
  8. Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer
    Raheleh Sheibani‐Tezerji, Carlos Uziel Pérez Malla, Gabriel Wasinger, Katarina Mišura, Astrid Haase, Anna Malzer, Jessica Kalla, Loan Tran, Gerda Egger · 2025 · Scientific Reports
  9. Regulation of androgen receptor expression by enhancer elements in prostate cancer
    Sudeep Khadka, Heeyoung Jeon, Arif Hussain, Jihao Qi · 2026 · Experimental & Molecular Medicine
  10. Assessing the Detection Power of Genome-Wide Copy Number Variation Profiles in Prostate Cancer Using Simulated Shallow Whole-Genome Sequencing Data
    Samhita Pamidimarri Naga, Peter H. J. Slootbeek, Sofie H. Tolmeijer, Christian Gilissen, Marjolijn J. L. Ligtenberg, Niven Mehra, Richarda M. de Voer · 2026 · JCO Clinical Cancer Informatics
  11. Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534
    Matthew R. Chrostek, James Robinson, Rajesh G. Krishnan, Evan Y. Yu, Luke T. Nordquist, Andrae Lavon Vandross, Mohamad Adham Salkeni, Jennifer L. Schehr, Matthew C. Mannino, Alyssa M. Hintz et al. · 2026 · Investigational New Drugs
  12. SOX11-mediated CXCL10/CXCR3 activation promotes neuroendocrine prostate cancer
    He-Kang Ding, Qingwei Meng, Kun He, Ziqi Chen, Yi Tang, Yige Yang, Xu Wang, Bing Zhao, Lili Xu · 2026 · Journal of Pharmacology and Experimental Therapeutics
  13. Targeting the RNA-binding motif protein 15 suppresses prostate cancer progression and hormone therapy resistance by promoting androgen receptor degradation
    Bintao Hu, Le Li, Zhenghui Jin, Qinyu Li, Yue Wu, Jie Chen, Jihong Liu, Chenglin Han, Tao Wang · 2026 · Molecular Biomedicine
  14. Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancer
    Chennan Li, JuanJuan Yin, Melissa L. Abel, Dana S. Vargas Solivan, Kinjal P. Bhadresha, Sumeyra Kartal, Samantha Nichols, Kanak Parmar, Joseph D. Twohig, Tri M. Truong et al. · 2026 · npj Precision Oncology
  15. Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
    Thaidy Moreno-Rodriguez, M ZHANG, Arian Lundberg, Raunak Shrestha, Martin Sjöström, Anupama Pasam, Joanna Chan, Lisa Devereux, Adam Foye, Xiaolin Zhu et al. · 2026 · Genome biology
  16. Mechanistic insights and molecular therapy for neuroendocrine prostate cancer
    Yichen Niu, Senyu Zhang, Shouyi Zhang, Jun Tao, Yuyan Zhu · 2026 · Frontiers in Oncology
  17. Broken and Reassembled: The Molecular Mechanisms and Clinical Consequences of Structural Genomic Variation
    Mohammad Fahad Ullah · 2026 · Molecular Syndromology
  18. PHLPP is neither a Phosphatase nor a Tumor Suppressor
    Thomas A. Leonard · 2026 · BioEssays
  19. Unifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer Management
    Kevin M. Koo · 2019 · Springer theses
  20. Discovery proteomics defines androgen-regulated glycoprotein networks in prostate cancer cells, as well as putative biomarkers of prostatic diseases
    Jordy J. Hsiao, Melinda M. Smits, Brandon H. Ng, Jinhee Lee, Michael E. Wright · 2021 · Scientific Reports
  21. Deoxynortryptoquivaline: A unique antiprostate cancer agent
    Yohko Momose Yamazaki, Manabu Kawada, Isao Momose · 2023 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
  22. Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308
    Shaghayegh Nouruzi, Fraser D. Johnson, Sahil Kumar, Olena Sivak, Nakisa Tabrizian, Milla Koistinaho, Anu Muona, Amina Zoubeidi · 2024 · Oncology Reports
  23. SV4GD: a comprehensive structural variation database specially for genetic diseases
    Lei Shi, Sainan Zhang, Ying Li, Hailong Li, Xin Wang, Meiyu Du, Meiyi Zhang, Liyan Ke, Yueni Zhang, Chao Xu et al. · 2024 · Nucleic Acids Research
  24. Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey‐Holden Prostate Cancer Academy Meeting
    Andrea K. Miyahira, Marina Nasrin Sharifi, Lisa N. Chesner, Asmaa El-Kenawi, Roni Haas, Laura A. Sena, Alok K. Tewari, Kenneth J. Pienta, Howard R. Soule · 2024 · The Prostate
  25. Rogue versus chromothriptic cell as biomarker of cancer
    Aleksandra Fučić, Vladimir Gennadyevich Druzhinin, Anna V. Aghajanyan, Predrag Slijepčević, М. Л. Баканова, Elizaveta D. Baranova, Varvara Ivanovna Minina, Tatiana Golovina, Kirill Kourdakov, Анна Александровна Тимофеева et al. · 2020 · Mutation Research/Reviews in Mutation Research
  26. Identification of Metastatic Cell Nucleus in Human Prostate Cancer by Electron Microscopy
    Akhouri A. Sinha · 2020 · Future Science OA
  27. The Promise and Perils of Sequencing Individual Prostate Cancer Nuclei
    Paul Christopher Boutros · 2018 · European Urology
  28. Reversing resistance to antiandrogens with a histone deacetylase inhibitor
    Anna C. Ferrari · 2018 · Oncotarget
  29. Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset
    Karen E. Knudsen, Felix Yi-Chung Feng · 2019 · European Urology
  30. Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Michael E. Fraser · 2019 · European Urology
  31. The Telomere Length Landscape of Prostate Cancer
    Julie M. Livingstone, Yu-Jia Shiah, Takafumi N. Yamaguchi, Lawrence E. Heisler, Vincent Huang, Robert Lesurf, Tsumugi Gebo, Benjamin Carlin, Stefan E. Eng, Erik Drysdale et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer
    Jyotsna Batra, Janaththani Panchadsaram, Gregor Tevž, Achala Fernando, Adil Malik, Anja Rockstroh, Thomas Kryza, Carina Walpole, Leire Moya, Melanie Lehman et al. · 2023 · Research Square
  33. Dosage Amplification Dictates Oncogenic Regulation by the NKX2-1 Lineage Factor in Lung Adenocarcinoma
    John L. Pulice, Matthew M. Meyerson · 2023 · SSRN Electronic Journal
  34. Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in AR -altered lethal prostate cancer
    Pradeep S. Chauhan, Irfan Alahi, Savar D. Sinha, Alexander L. Shiang, Ryan Mueller, Jace B. Webster, Ha X. Dang, Debanjan Saha, Lilli J. Greiner, Breanna Yang et al. · 2023 · medRxiv
  35. Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer
    Larysa Poluben, Mannan Nouri, Jiaqian Liang, Andreas S. Varkaris, Betul Ersoy-Fazlioglu, Olga S. Voznesensky, Irene I. Lee, Xintao Qiu, Laura Cato, Ji-Heui Seo et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  36. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
    Sander B. Frank, Thomas W. Persse, Ilsa Coleman, Armand Bankhead, Dapei Li, Navonil De Sarkar, Divin Wilson, Dmytro Rudoy, Manasvita Vashisth, Patty Galipeau et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  37. TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications
    Arunachalam Sekar, Rishita Chatterjee, Boobash Raj Selvadurai, Lipika R. Pal, Aakanksha Verma, Nishanth Belugali Nataraj, Diana Drago Garcia, Suvendu Giri, Alessandro Genna, Feride Karatekin et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  38. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
    Sander B. Frank, Thomas W. Persse, Ilsa Coleman, Armand Bankhead, Dapei Li, Navonil De Sarkar, Divin Wilson, Dmytro Rudoy, Manasvita Vashisth, Patty Galipeau et al. · 2025 · eLife
  39. Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancer
    Chennan Li, JuanJuan Yin, Melissa L. Abel, Dana S. Vargas Solivan, Kinjal P. Bhadresha, Sumeyra Kartal, Samantha Nichols, Kanak Parmar, Joseph D. Twohig, Tri M. Truong et al. · 2026 · medRxiv
  40. Chromatin reprogramming as adaptation mechanism in advanced prostate cancer
    Alfonso Urbanucci · 2018 · European Urology Supplements
  41. Towards a New Classification for Metastatic Prostate Cancer
    Joaquı́n Mateo, Joan Carles · 2018 · European Urology
  42. Clinical implications of genetic aberrations in metastatic prostate cancer
    Zachery Roger Reichert, Rana R. McKay · 2019 · Current Opinion in Urology
  43. Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancer
    Zsófia M. Sztupinszki, Miklós Dióssy, Marcin Krzystanek, Judit Börcsök, Mark M. Pomerantz, Viktória Tisza, Sándor Spisák, Orsolya Rusz, István Csabai, Matthew L. Freedman et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  44. Single-cell dissection of a rare human prostate basal cell carcinoma
    Xianbin Su, Qi Long, Juanjie Bo, Yi Y. Shi, Linan Zhao, Yingxin Lin, Qing Luo, Shila Ghazanfar, Chao Zhang, Qiang Liu et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  45. AR Gain: Resistance Mechanism or Measure of Tumor Burden?
    David James VanderWeele · 2019 · JCO Precision Oncology
  46. Low ribosomal RNA genes copy number provoke genomic instability and chromosomal segment duplication events that modify global gene expression and plant-pathogen response
    Ariadna Picart-Picolo, Stefan Grob, Nathalie Picault, Michal Franek, Thierry Halter, Tom R. Maier, Christel Llauro, Edouard Jobet, Panpan Zhang, Paramasivan Vijayapalani et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  47. Dysregulated gene expression through TP53 promoter swapping in osteosarcoma
    Karim H. Saba, Valeria Difilippo, Michal B Kovac, Louise Cornmark, Linda Magnusson, Jenny Nilsson, Hilda van den Bos, Diana C.J. Spierings, Mahtab Bidgoli, Tord Jonson et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  48. [Palmitoylome profiling indicates that androgens promote the palmitoylation of metabolism-related proteins in prostate cancer-derived LNCaP cells].
    W Q Li, S M Ren, Xingbo Long, Yonglu Tian · 2020 · PubMed Central
  49. Autoantibody landscape of advanced prostate cancer
    William S. Chen, Winston A. Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha, Minlu Zhang, Adam Foye, Ignacio Baselga-Carretero, Ivan Garcilazo Perez et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  50. Genomic Analysis And Engineering Of Chinese Hamster Ovary Cells For Improved Therapeutic Protein Production
    Sofie A. O’Brien · 2020 · University of Minnesota Digital Conservancy (University of Minnesota)
  51. Molekularpathologie und Biomarker
    Jutta Kirfel, Anne Offermann · 2020 · Springer eBooks
  52. CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer
    Ning Zhao, Kai R. Trepka, Yung-Hua Wang, Shalini Chopra, Nima Hooshdaran, Hyun‐Jung Kim, Jie Zhuo, Shion An Lim, Jianing Yang, Kevin Leung et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  53. Design and Implementation of Cancer Structural Variants Hotspot Detection and Annotation Software
    Xiaomin Lv, Siyu Liu, Shuai Jiang · 2021 · Lecture notes on data engineering and communications technologies
  54. Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole Genome Sequencing
    Minh‐Tam Pham, Harshath Gupta, Anuj Kumar Gupta, Ajay M. Vaghasia, Alyza M. Skaist, McKinzie A. Garrison, Jonathan B. Coulter, Michael C. Haffner, William B. Isaacs, Sarah J. Wheelan et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  55. Genomic characterization of treatment-associated small cell neuroendocrine carcinoma of the prostate
    Ivan de Kouchkovsky, David Alan Quigley, Eric Jay Small, Rahul Raj Aggarwal · 2021 · Journal of Translational Genetics and Genomics
  56. Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer
    Natasha Kyprianou, Fabrice Lucien · 2021 · International Journal of Molecular Sciences
  57. Modulation of the Androgen Receptor Axis
    Michael L. Mohler, James T. Dalton · 2021 · Wiley eBooks
  58. Durabilidad del sirope de chocolate
    O. A. Díaz Armada, Zaimarelis Bernal González, J. González, César Fireth Pozo Beltrán · 1999 · Alimentaria
  59. Decoding androgen receptor inhibitor resistance in prostate cancer
    Sander A. L. Palit · 2022
  60. Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
    Hanny, Xuesen · 2022 · Oncoscience
  61. Faculty Opinions recommendation of Genomic correlates of clinical outcome in advanced prostate cancer.
    Alvin M. Matsumoto · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  62. Faculty Opinions recommendation of Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
    Charlotte Lynne Bevan, Theodora A. Constantin · 2021 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  63. Androgen Receptor Reprogramming Demarcates Prognostic Gene Sets In Prostate Cancer
    Tesa Severson, Xintao Qiu, Mohammed Alshalalfa, Martin Sjöström, Andries Marinus Bergman, Henry W. Long, Felix Yi-Chung Feng, Matthew L. Freedman, Wilbert T. Zwart, Mark M. Pomerantz · 2022 · Research Square
  64. Avaliação da expressão gênica dos coativadores da família p160 na progressão do carcinoma prostático
    Poliana Romão da Silva · 2022
  65. Treatment-mediated selection of lethal prostate cancer clones defined by copy number architectures
    A. M. Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, Anuradha Jayaram, Stephen Q. Wong, Scott Williams, Anupama Pasam, Anna Trigos, Blanca Trujillo, Emily Grist et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  66. Peer Review #1 of "Integrating multi-type aberrations from DNA and RNA through dynamic mapping gene space for subtype-specific breast cancer driver discovery (v0.1)"
    2023 · PeerJ
  67. Diminished PDE4D7 Expression is Associated with Treatment-Resistant, Lethal Prostate Cancer and Manifests with Impaired Androgen Response, Neuroendocrine Differentiation and Alterations in DNA Repair
    Chloe Gulliver, Sebastian Huss, Axel Semjonow, George S. Baillie, Ralf Hoffmann · 2023 · Research Square
  68. Prostate Cancer
    Wolfgang A. Schulz · 2023 · Springer eBooks
  69. Supplementary Data from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
    Yingming Li, Rendong Yang, Christine M. Henzler, Yeung Ho, Courtney N. Passow, Benjamin Auch, Suzanne Carreira, Daniel Nava Rodrigues, Claudia Maria Bertan, Tae Hyun Hwang et al. · 2023
  70. Data from BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
    Evan W. Warner, Cameron Herberts, Simon Yuen Fai Fu, Steven Yip, Amanda Wong, Gang Wang, Elie J. Ritch, Andrew J. Murtha, Gillian Rae Vandekerkhove, Nicolette M. Fonseca et al. · 2023
  71. Data from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
    Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona J. Lewis, Audrey Phone, Eric Jay Small, Terence W. Friedlander, Lawrence H. Fong, Pamela L. Paris et al. · 2023
  72. Data from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
    Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona J. Lewis, Audrey Phone, Eric Jay Small, Terence W. Friedlander, Lawrence H. Fong, Pamela L. Paris et al. · 2023
  73. Data from BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
    Evan W. Warner, Cameron Herberts, Simon Yuen Fai Fu, Steven Yip, Amanda Wong, Gang Wang, Elie J. Ritch, Andrew J. Murtha, Gillian Rae Vandekerkhove, Nicolette M. Fonseca et al. · 2023
  74. Data from Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
    Diana C. DeLucia, Thomas M. Cardillo, Lisa S. Ang, Mark P. Labrecque, Ailin Zhang, James E. Hopkins, Navonil De Sarkar, Ilsa M. Coleman, Rui M. Gil da Costa, Eva Corey et al. · 2023
  75. Data from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
    Adam G. Sowalsky, Ines Figueiredo, Rosina T. Lis, Ilsa M. Coleman, Bora Gürel, Denisa Bogdan, Wei Yuan, Joshua W. Russo, John R. Bright, Nichelle C. Whitlock et al. · 2023
  76. Data from Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole-Genome Sequencing
    Minh‐Tam Pham, Anuj Gupta, Harshath Gupta, Ajay M. Vaghasia, Alyza M. Skaist, McKinzie A. Garrison, Jonathan B. Coulter, Michael C. Haffner, S. Lilly Zheng, Jianfeng Xu et al. · 2023
  77. Data from Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole-Genome Sequencing
    Minh‐Tam Pham, Anuj Gupta, Harshath Gupta, Ajay M. Vaghasia, Alyza M. Skaist, McKinzie A. Garrison, Jonathan B. Coulter, Michael C. Haffner, S. Lilly Zheng, Jianfeng Xu et al. · 2023
  78. Supplementary Data 3 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
    Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J. Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James Robert Bischoff, Georges Habineza et al. · 2023
  79. Cancers hormono-dépendants : sein et prostate
    Jacques Robert · 2023 · Elsevier eBooks
  80. Data from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
    Lucie Van Emmenis, Sheng‐Yu Ku, Kaitlyn M. Gayvert, Jonathan R. Branch, Nicholas J. Brady, Subhasree Basu, Mike R. Russell, Joanna Cyrta, Aram Vosoughi, Verena Wilbeth Sailer et al. · 2023
  81. Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer
    Bin Fu, Liyang Wang, Tianwei Jia, Zhao Wei, Nuosu Nama, Jiaqian Liang, Xinghua Liao, Xiaming Liu, Yanfei Gao, Xiaoqiang Liu et al. · 2023 · The Prostate
  82. Genomic and epigenomic evolution of metastatic prostate cancer: the first warm autopsy in China
    Wenhui Zhang, Yan Wang, Min Qu, Haoqing Shi, Xin L. Lu, Qingsong Yang, Fang Liu, Tao Wang, Ziwei Wang, Bijun Lian et al. · 2023 · medRxiv
  83. Genomic and epigenomic evolution of metastatic prostate cancer: the first warm autopsy in China
    Wenhui Zhang, Yan Wang, Min Qu, Haoqing Shi, Xin L. Lu, Qingsong Yang, Fang Liu, Tao Wang, Ziwei Wang, Bijun Lian et al. · 2023
  84. Genomic and epigenomic evolution of metastatic prostate cancer: the first warm autopsy in China
    Wenhui Zhang, Yan Wang, Min Qu, Haoqing Shi, Xin L. Lu, Qingsong Yang, Fang Liu, Tao Wang, Ziwei Wang, Bijun Lian et al. · 2023
  85. Prostatakrebs
    Wolfgang A. Schulz · 2024 · Springer eBooks
  86. Diagnostic, Prognostic and Theranostic Potential of miRNAs in Prostate Cancer
    Ana R. Savic-Radojevic, Marija S. Pljesa-Ercegovac · 2024 · Springer eBooks
  87. A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy
    Aishwarya Subramanian, Meng Zhang, Marina Nasrin Sharifi, Thaidy Moreno-Rodriguez, Eric Li-Len Feng, Nicholas Robert Rydzewski, Raunak Shrestha, Xiaolin Zhu, Shuang George Zhao, Rahul Raj Aggarwal et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  88. N6-methyladenosine-modified circRPS6KC1 regulated cell senescence in prostate cancer via FOXM1/PCNA axis
    Xuan Shu, Jiahe Yi, Jiangfeng Li, Yufan Ying, Yijie Tang, Ziyan Chen, Jiaming Wang, Fenghao Zhang, Dingheng Lu, Yuqing Wu et al. · 2024 · Research Square
  89. The Assessment of IL-4 and IgG1 Levels in Patients with Rheumatoid Arthritis and Periodontitis: A Serological Study in Hilla City, Iraq
    Mustafa Ibrahim Al Amery, Huda Abbas Mohammed, Zeyad Nazar Majeed · 2024 · Medical Journal of Babylon
  90. Histopathological and Molecular Markers of Metastatic Prostate Cancer
    Ceyda Nur Zaim, Nagehan Ersoy Tunalı · 2024
  91. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
    Sander B. Frank, Thomas W. Persse, Ilsa Coleman, Armand Bankhead, Dapei Li, Navonil De Sarkar, Divin Wilson, Dmytro Rudoy, Manasvita Vashisth, Patty Galipeau et al. · 2024 · eLife
  92. FuSViz—visualization and interpretation of structural variation using cancer genomics and transcriptomics data
    Sen Zhao, Sigve Nakken, Daniel Vodák, Eivind J. Hovig · 2025 · Nucleic Acids Research
  93. Goistrat: gene-of-interest-based sample stratification for the evaluation of functional differences
    Carlos Uziel Pérez Malla, Jessica Kalla, Andreas Tiefenbacher, Gabriel Wasinger, Kilian Kluge, Gerda Egger, Raheleh Sheibani‐Tezerji · 2025 · BMC Bioinformatics
  94. Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer
    Marjorie L. Roskes, Alexander Martinez‐Fundichely, Sandra M. Cohen, Metin Balaban, Chen Khuan Wong, Weiling Li, Tonatiuh A. Gonzalez, Anisha B. Tehim, Hao Xu, Shahd ElNaggar et al. · 2025 · medRxiv
  95. Transcriptome-wide association studies implicate RCC1 and PHACTR4 in prostate cancer survival
    Weijia Fu, Joseph H. Rothstein, Olle Melander, Hans G. Lilja, Weiva Sieh, Xiaoyu Song, Robert J. Klein · 2026 · European Journal of Human Genetics
  96. Psammomatous Calcifications Identified in Targeted Needle Biopsies and Radical Prostatectomy From IDH1 Mutant Prostatic Adenocarcinoma
    Yang Zong, Mark Sharobim, Edward M. Lawrence, Rong Hu, Wei Huang, Daniel D. Shapiro · 2025 · The American Journal of Surgical Pathology
  97. Genomic Divergence Between Matched Primary and Metastatic Tumors Across Cancer Types: A Pan-Cancer Analysis of 5,692 Samples
    Yakup Ergün · 2025 · medRxiv
  98. Somatic evolution of prostate cancer: mutation, selection, and epistasis across disease stages
    Moein Rajaei, Alexander Yang, Kira A. Glasmacher, Christopher N. Cross, Nic Fisk, Elizabeth B. Perry, Jeff Mandell, S. Gaffney, T. Yamaguchi, J. Livingstone et al. · 2025 · bioRxiv
  99. Prioritizing context-specific genetic risk mechanisms in 11 solid cancers
    Xueyao Wu, Artem Kim, Charles E. Breeze, Tracy A. O’Mara, Dhanya Ramachandran, Thilo Dörk, Stella Koutros, Nathaniel Rothman, Ludmila Prokunina‐Olsson, Nicholas Mancuso et al. · 2026 · JNCI Journal of the National Cancer Institute
  100. cfOncoXpress: Tumor gene expression prediction from cell-free DNA whole-genome sequences
    Weiling Li, Marjorie L. Roskes, Alexander Martinez‐Fundichely, Ekta Khurana · 2025 · bioRxiv (Cold Spring Harbor Laboratory)